{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017858","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.532112+00:00","generated_at":"2026-05-22T03:06:46.678748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed Q1 revenue up 23% to $92.8M; net loss widens to $1.42/sh; brensocatib PDUFA Aug 12","bullets":["ARIKAYCE total revenue $92.8M (+23% YoY); FY2025 guidance reaffirmed $405-425M.","Net loss $256.6M ($1.42/sh) vs $157.1M ($1.06/sh); R&D $152.6M, SG&A $147.5M.","Brensocatib NDA accepted; PDUFA date Aug 12, 2025; EU/UK MAA accepted.","TPIP Phase 2b in PAH completed; topline data expected June 2025; Phase 3 in PH-ILD planned H2 2025.","$569.5M convertible notes redeemed; cash & securities $1.2B as of March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017858","json":"https://secwatch.observer/filing/0001140361-25-017858.json","markdown":"https://secwatch.observer/filing/0001140361-25-017858.md","text":"https://secwatch.observer/filing/0001140361-25-017858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/0001140361-25-017858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:06:46.678748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}